Cargando…

Survival with chronic myeloid leukaemia after failing milestones

Therapy after failing response milestones in CML is controversial. Risks associated with comorbidities, drug toxicities or transplantation may preclude switching to another tyrosine kinase inhibitor (TKI) or other treatments. No information on long-term survival of failing patients is available. To...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lauseker, Michael, Hehlmann, Rüdiger, Hochhaus, Andreas, Saußele, Susanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624616/ https://www.ncbi.nlm.nih.gov/pubmed/37726340 http://dx.doi.org/10.1038/s41375-023-02028-2

Ejemplares similares

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022)

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
por: Pfirrmann, Markus, et al.
Publicado: (2020)

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
por: Steegmann, J L, et al.
Publicado: (2016)

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
por: Saussele, Susanne, et al.
Publicado: (2018)

Chronic Myeloid Leukemia in 2020
por: Hehlmann, Rüdiger
Publicado: (2020)

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV
por: Kalmanti, Lida, et al.
Publicado: (2013)

The concept of treatment-free remission in chronic myeloid leukemia
por: Saußele, S, et al.
Publicado: (2016)

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
por: Proetel, Ulrike, et al.
Publicado: (2014)

P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL
por: Le Coutre, Philipp, et al.
Publicado: (2023)

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
por: Padula, William V., et al.
Publicado: (2016)

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
por: Miranda, M B, et al.
Publicado: (2016)

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
por: Cross, Nicholas C. P., et al.
Publicado: (2023)

S155: PROGNOSTIC FACTORS FOR 3-YEAR MAJOR MOLECULAR RESPONSE MAINTENANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE EUROPEAN STOP KINASE INHIBITORS (EURO-SKI) TRIAL
por: Pfirrmann, Markus, et al.
Publicado: (2023)

Asciminib for chronic myeloid leukaemia
Publicado: (2022)

Chronic Myeloid Leukaemia: Report of a Case Surviving Ten Years
por: Hird, Alan J.
Publicado: (1949)

Prof. Michele Baccarani. August 16, 1942 to December 20, 2021: a gifted life in haematology
por: Saglio, Giuseppe, et al.
Publicado: (2022)

Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy
por: Pavlík, Tomáš, et al.
Publicado: (2011)

Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer
por: Hofheinz, R-D, et al.
Publicado: (2004)

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
por: Michel, Christian, et al.
Publicado: (2019)

Genomic Instability in Context of the Chromosomal Theory
por: Fabarius, Alice, et al.
Publicado: (2008)

Chronic myeloid leukaemia with marked thrombocytosis
por: Ooi, Jun, et al.
Publicado: (2020)

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
por: Ernst, Thomas, et al.
Publicado: (2023)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

High-risk additional chromosomal abnormalities at low blast counts herald death by CML
por: Hehlmann, Rüdiger, et al.
Publicado: (2020)

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
por: Schönfeld, Lioba, et al.
Publicado: (2022)

COVID-19 in persons with chronic myeloid leukaemia
por: Li, Weiming, et al.
Publicado: (2020)

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML
por: Hehlmann, Rüdiger, et al.
Publicado: (2020)

Chronic Myeloid Leukaemia in The 21st Century
por: Frazer, Rachel, et al.
Publicado: (2007)

Isolated Ocular Manifestations in Chronic Myeloid Leukaemia
por: Maniam, Anita, et al.
Publicado: (2021)

Two ophthalmic presentations of chronic myeloid leukaemia
por: Kiernan, Miles, et al.
Publicado: (2022)

Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network
por: Schäfer, Vivien, et al.
Publicado: (2021)

Chemotherapy of the Myeloid Leukaemias
por: Stuart, John
Publicado: (1980)

Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial
por: Hofheinz, R-D, et al.
Publicado: (2004)

Why are patients with chronic myeloid leukaemia (non-)adherent?
por: Abraham, I, et al.
Publicado: (2012)

The underestimated role of basophils in Ph(+) chronic myeloid leukaemia
por: Valent, Peter, et al.
Publicado: (2018)

Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
por: Carrà, Giovanna, et al.
Publicado: (2019)

Acute abdomen in a patient with chronic myeloid leukaemia
por: Voppuru, Saiesh Reddy, et al.
Publicado: (2020)

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
por: Hochhaus, Andreas, et al.
Publicado: (2020)

Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia
por: Samaiya, Misti, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_a6tr6h5go28b38qc186j2ut1qm